Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 75c
Tweet
Share
E-mailGet Alerts BLPH Hot Sheet
Join SI Premium – FREE
Bellerophon Therapeutics (NASDAQ: BLPH) reported Q1 EPS of $0.27, $0.75 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $5.64 million versus the consensus estimate of $0 .
For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Halozyme adds biotech executive Appelhans to its board
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
